Drugs for Neglected Diseases initiative will conduct Phase III, multi-country trials of a dengue candidate developed by Visterra and licensed by Serum Institute. The monoclonal antibody was developed on the same platform as Otsuka's Voyxact
Drugs for Neglected Diseases initiative will conduct Phase III, multi-country trials of a dengue candidate developed by Visterra and licensed by Serum Institute. The monoclonal antibody was developed on the same platform as Otsuka's Voyxact